Last reviewed · How we verify
Doravirine/Lamivudine/Tenofovir
Doravirine/Lamivudine/Tenofovir is a Antiretroviral combination (NNRTI + NRTI + NtRTI) Small molecule drug developed by Thomas Jefferson University. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve adults. Also known as: Delstrigo.
This fixed-dose combination inhibits HIV reverse transcriptase and integrase to block viral replication.
This fixed-dose combination inhibits HIV reverse transcriptase and integrase to block viral replication. Used for HIV-1 infection in treatment-naïve adults.
At a glance
| Generic name | Doravirine/Lamivudine/Tenofovir |
|---|---|
| Also known as | Delstrigo |
| Sponsor | Thomas Jefferson University |
| Drug class | Antiretroviral combination (NNRTI + NRTI + NtRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase, while lamivudine and tenofovir are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) that are incorporated into viral DNA to terminate chain elongation. Together, these three agents target different steps of HIV replication to suppress viral load.
Approved indications
- HIV-1 infection in treatment-naïve adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Renal impairment (tenofovir-related)
Key clinical trials
- Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (PHASE2)
- Doravirine Dose Optimisation in Pregnancy (PHASE4)
- Efficacy and Safety of Doravirine in the Rapid Initiation (PHASE4)
- DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study (PHASE4)
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Doravirine/Lamivudine/Tenofovir CI brief — competitive landscape report
- Doravirine/Lamivudine/Tenofovir updates RSS · CI watch RSS
- Thomas Jefferson University portfolio CI
Frequently asked questions about Doravirine/Lamivudine/Tenofovir
What is Doravirine/Lamivudine/Tenofovir?
How does Doravirine/Lamivudine/Tenofovir work?
What is Doravirine/Lamivudine/Tenofovir used for?
Who makes Doravirine/Lamivudine/Tenofovir?
Is Doravirine/Lamivudine/Tenofovir also known as anything else?
What drug class is Doravirine/Lamivudine/Tenofovir in?
What development phase is Doravirine/Lamivudine/Tenofovir in?
What are the side effects of Doravirine/Lamivudine/Tenofovir?
What does Doravirine/Lamivudine/Tenofovir target?
Related
- Drug class: All Antiretroviral combination (NNRTI + NRTI + NtRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Thomas Jefferson University — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve adults
- Also known as: Delstrigo
- Compare: Doravirine/Lamivudine/Tenofovir vs similar drugs
- Pricing: Doravirine/Lamivudine/Tenofovir cost, discount & access